- Home
- SLGL vs RLMD Comparison
SLGL vs RLMD Comparison
Compare SLGL & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- RLMD
- Stock Information
- Founded
- SLGL 1997
- RLMD 2004
- Country
- SLGL Israel
- RLMD United States
- Employees
- SLGL N/A
- RLMD N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- SLGL Health Care
- RLMD Health Care
- Exchange
- SLGL Nasdaq
- RLMD Nasdaq
- Market Cap
- SLGL 19.3M
- RLMD 22.0M
- IPO Year
- SLGL 2018
- RLMD N/A
- Fundamental
- Price
- SLGL $7.26
- RLMD $0.61
- Analyst Decision
- SLGL Buy
- RLMD Buy
- Analyst Count
- SLGL 1
- RLMD 3
- Target Price
- SLGL $40.00
- RLMD $5.00
- AVG Volume (30 Days)
- SLGL 25.3K
- RLMD 457.1K
- Earning Date
- SLGL 08-15-2025
- RLMD 08-06-2025
- Dividend Yield
- SLGL N/A
- RLMD N/A
- EPS Growth
- SLGL N/A
- RLMD N/A
- EPS
- SLGL N/A
- RLMD N/A
- Revenue
- SLGL $12,103,000.00
- RLMD N/A
- Revenue This Year
- SLGL N/A
- RLMD N/A
- Revenue Next Year
- SLGL $31.17
- RLMD N/A
- P/E Ratio
- SLGL N/A
- RLMD N/A
- Revenue Growth
- SLGL 603.66
- RLMD N/A
- 52 Week Low
- SLGL $3.34
- RLMD $0.24
- 52 Week High
- SLGL $16.50
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- SLGL 52.97
- RLMD 47.24
- Support Level
- SLGL $7.02
- RLMD $0.67
- Resistance Level
- SLGL $7.58
- RLMD $0.74
- Average True Range (ATR)
- SLGL 0.37
- RLMD 0.07
- MACD
- SLGL 0.02
- RLMD -0.03
- Stochastic Oscillator
- SLGL 41.28
- RLMD 25.79
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.